Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage
The European Patent Office has said it has invalidated a patent held by Moderna on mRNA-based COVID-19 vaccines, the latest development in an increasingly acrimonious disp
At DPHARM 2023 in Boston, Pfizer announced that it has taken the first steps towards sharing clinical trial participants’ own data with them – something participants have sought for years.<
Already a mainstay of prostate cancer therapy, Pfizer and Astellas’ Xtandi has picked up a new approval in the US that could reinvigorate the drug, even as it approaches i
Pfizer has fleshed out some more of the details of its wide-ranging cost-cutting drive announced last month, revealing that around 500 jobs will go in the UK, including at
It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the f